JP6556753B2 - トリマルトール鉄（ｉｉｉ）の投与計画 - Google Patents

トリマルトール鉄（ｉｉｉ）の投与計画 Download PDF

Info

Publication number
JP6556753B2
JP6556753B2 JP2016562082A JP2016562082A JP6556753B2 JP 6556753 B2 JP6556753 B2 JP 6556753B2 JP 2016562082 A JP2016562082 A JP 2016562082A JP 2016562082 A JP2016562082 A JP 2016562082A JP 6556753 B2 JP6556753 B2 JP 6556753B2
Authority
JP
Japan
Prior art keywords
iron
iii
trimaltol
formulation
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016562082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501235A5 (enExample
JP2017501235A (ja
Inventor
シュワイガー，クリスティアン
ステリット，カール・アンドリュー
ハウエル，ジュリアン・デヴィッド
Original Assignee
アイアン・セラピューティクス・ホールディングス・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201400171A external-priority patent/GB201400171D0/en
Priority claimed from GB201418708A external-priority patent/GB201418708D0/en
Application filed by アイアン・セラピューティクス・ホールディングス・アクチェンゲゼルシャフト filed Critical アイアン・セラピューティクス・ホールディングス・アクチェンゲゼルシャフト
Publication of JP2017501235A publication Critical patent/JP2017501235A/ja
Publication of JP2017501235A5 publication Critical patent/JP2017501235A5/ja
Application granted granted Critical
Publication of JP6556753B2 publication Critical patent/JP6556753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016562082A 2014-01-06 2015-01-06 トリマルトール鉄（ｉｉｉ）の投与計画 Active JP6556753B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1400171.3 2014-01-06
GB201400171A GB201400171D0 (en) 2014-01-06 2014-01-06 Dosage regimen
GB1418708.2 2014-10-21
GB201418708A GB201418708D0 (en) 2014-10-21 2014-10-21 Dosage regimen
PCT/IB2015/050098 WO2015101971A1 (en) 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019072643A Division JP2019131592A (ja) 2014-01-06 2019-04-05 トリマルトール鉄（ｉｉｉ）の投与計画

Publications (3)

Publication Number Publication Date
JP2017501235A JP2017501235A (ja) 2017-01-12
JP2017501235A5 JP2017501235A5 (enExample) 2017-09-28
JP6556753B2 true JP6556753B2 (ja) 2019-08-07

Family

ID=52432872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016562082A Active JP6556753B2 (ja) 2014-01-06 2015-01-06 トリマルトール鉄（ｉｉｉ）の投与計画
JP2019072643A Withdrawn JP2019131592A (ja) 2014-01-06 2019-04-05 トリマルトール鉄（ｉｉｉ）の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019072643A Withdrawn JP2019131592A (ja) 2014-01-06 2019-04-05 トリマルトール鉄（ｉｉｉ）の投与計画

Country Status (12)

Country Link
US (1) US10179120B2 (enExample)
EP (1) EP3091974B1 (enExample)
JP (2) JP6556753B2 (enExample)
KR (1) KR102351422B1 (enExample)
CN (2) CN106413706A (enExample)
AU (1) AU2015204192B2 (enExample)
BR (1) BR112016015766A2 (enExample)
CA (1) CA2934836C (enExample)
ES (1) ES2785391T3 (enExample)
IL (1) IL246613B (enExample)
SI (1) SI3091974T1 (enExample)
WO (1) WO2015101971A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2785391T3 (es) 2014-01-06 2020-10-06 Shield Tx Uk Ltd Régimen de dosificación de trimaltol férrico
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
CN109071481B (zh) 2016-03-31 2022-09-30 英国神盾Tx股份有限公司 用于由元素铁产生麦芽酚铁组合物的方法
CN109310667B (zh) * 2016-03-31 2022-01-11 英国神盾Tx股份有限公司 用于治疗或预防癌症和肿瘤的麦芽酚铁组合物
AU2017242901B2 (en) * 2016-03-31 2020-11-19 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
CN109311837B (zh) 2016-03-31 2022-09-30 英国神盾Tx股份有限公司 用于由氢氧化亚铁产生麦芽酚铁组合物的方法
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150213B (it) * 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
RO113611B1 (ro) * 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
DE69633178T2 (de) 1995-06-10 2005-08-11 Vitra Pharmaceuticals Ltd., Saffron Walden Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ES2236300T3 (es) 2000-09-19 2005-07-16 Vitra Pharmaceuticals Ltd. Composiciones de hierro.
US20050118291A1 (en) * 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
US20070087036A1 (en) * 2005-05-03 2007-04-19 Durschlag Maurice E Edible film for transmucosal delivery of nutritional supplements
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
GB201101370D0 (en) * 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
JP5856725B2 (ja) * 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
ES2785391T3 (es) 2014-01-06 2020-10-06 Shield Tx Uk Ltd Régimen de dosificación de trimaltol férrico
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen

Also Published As

Publication number Publication date
EP3091974A1 (en) 2016-11-16
IL246613A0 (en) 2016-08-31
KR20160105499A (ko) 2016-09-06
EP3091974B1 (en) 2020-04-01
CN114010629A (zh) 2022-02-08
SI3091974T1 (sl) 2020-08-31
IL246613B (en) 2020-05-31
CN106413706A (zh) 2017-02-15
CA2934836C (en) 2022-03-22
AU2015204192B2 (en) 2020-03-26
JP2017501235A (ja) 2017-01-12
JP2019131592A (ja) 2019-08-08
ES2785391T3 (es) 2020-10-06
KR102351422B1 (ko) 2022-01-13
US20160324822A1 (en) 2016-11-10
BR112016015766A2 (pt) 2017-08-08
WO2015101971A1 (en) 2015-07-09
US10179120B2 (en) 2019-01-15
CA2934836A1 (en) 2015-07-09
AU2015204192A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
JP6556753B2 (ja) トリマルトール鉄（ｉｉｉ）の投与計画
KR102150135B1 (ko) 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
US20130225639A1 (en) Altering pharmacokinetics of pirfenidone therapy
CA2631646C (en) Methods of reducing adverse events associated with pirfenidone therapy
TR201902517T4 (tr) 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
US10786514B2 (en) Dosage regiment of ferric maltol
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
KR20160118234A (ko) 만성 신장병의 진행 억제 또는 개선제
JP2019501184A (ja) 鉄化合物及びシトレート化合物を用いる併用療法
US9402864B2 (en) Oral iron deficiency therapy
CN117138047B (zh) Tlr4抑制剂在制备缓解索拉非尼所致胃肠道毒性的药物中的应用
KR100631873B1 (ko) 생체이용율이 증진된 알렌드론산 제제
Liza Impact of Different Supplement Drugs on the Dissolution Profile of Zantac and Xantid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190710

R150 Certificate of patent or registration of utility model

Ref document number: 6556753

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250